JusticeItaly Official institution
Italy changes marketing permission for Eribulina Glenmark medicine
Italy's medicines agency, AIFA, has published a notice saying the marketing authorization for a human medicine called Eribulina Glenmark, which contains eribulin, has been changed. Marketing authorization is the official permission that allows a drug to be sold. The notice, reference 26A05650, does not say what the change is in the text provided.
This summary was generated by AI; the official source prevails.
What does it mean?
Italy's medicines regulator has officially changed the permission under which the cancer drug Eribulina Glenmark can be sold. The notice does not explain what was changed, so the details are only available in the full official document.
Who is affected?
Patients who use eribulin medicines and the companies that sell them in Italy.